Kuros BiosciencesCSBTF 71 Return-on-Tangible-Asset is 11.37% as of Dec. 2025. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.44 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 61.92% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kuros Biosciences's annualizedNet Income for the quarter that ended in Dec. 2025 was $10.4 Mil. Kuros Biosciences's average total tangible assets for the quarter that ended in Dec. 2025 was $91.8 Mil. Therefore, Kuros Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 11.37%.
The historical rank and industry rank for Kuros Biosciences's Return-on-Tangible-Asset or its related term are showing as below:
CSBTF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -133.2 Med: -39.29 Max: 3.78
Current: 3.78
During the past 13 years, Kuros Biosciences's highest Return-on-Tangible-Asset was 3.78%. The lowest was -133.20%. And the median was -39.29%.
CSBTF's Return-on-Tangible-Asset is ranked better than 61.92% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs CSBTF: 3.78
Kuros Biosciences (OTCPK:CSBTF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Kuros Biosciences Return-on-Tangible-Asset Related Terms
Kuros Biosciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBTF vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Kuros Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 11.37% mean?
Kuros Biosciences (CSBTF) has a Return-on-Tangible-Asset of 11.37% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #326 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 38.1%.
Is Kuros Biosciences' Return-on-Tangible-Asset too high?
Kuros Biosciences' current Return-on-Tangible-Asset is 11.37%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Kuros Biosciences' value of 11.37% is 1810.9% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #326 out of 856 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #326 out of 856 companies for Return-on-Tangible-Asset. This puts Kuros Biosciences in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.60. Kuros Biosciences' value of 11.37% is 1810.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Return-on-Tangible-Asset of 11.37% is 1810.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Return-on-Tangible-Asset is 11.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.44, compared to a current price of $22.72 — trading 58.3% below its estimated fair value. The current Return-on-Tangible-Asset is 11.37% and 1810.9% above the Medical Devices & Instruments industry median of 0.60. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Return-on-Tangible-Asset is 11.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.3% below its estimated GF Value™ of $54.44.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Return-on-Tangible-Asset: 11.37%
GF Value™: $54.44 vs. price of $22.72 (58.3% below fair value)
Industry Position: 1810.9% above the Medical Devices & Instruments median (#326 of 856)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
